TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24184411

Group type: EXPERIMENTAL
Intervention: Low glycaemic load breakfast
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High glycaemic load breakfast
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water breakfast
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (matched for age, IQ, BMI, waist circumference, and depression)
Number of subjects: 60
Study: 22709245

Group type: EXPERIMENTAL
Intervention: Video Interaction Guidance (VIG) for parents of premature infants
Number of subjects: 210

Group type: COMPARATOR
Intervention: Care as usual for premature infants and their parents
Number of subjects: 210

Group type: COMPARATOR
Intervention: Care as usual for full term infants and their parents
Number of subjects: 210
Study: 19786967

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss programs (BWL)
Number of subjects: 298
Study: 17531001

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IL-2 with HAART
Number of subjects: 25

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 25
Study: 15511696

Group type: EXPERIMENTAL
Intervention: Zonisamide (400 mg QD)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 11578886

Group type: EXPERIMENTAL
Intervention: Classical intubating position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 20
Study: 9569076

Group type: EXPERIMENTAL
Intervention: Physical training (bicycle exercise and step aerobics) over a 6 week period
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 14
Study: 8036045

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate 40 mg/kg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate 25 mg/kg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Erythromycin (both dosages)
Number of subjects: 14
Study: 2838288

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Radiotherapy with chemotherapy (RT-CT)
Number of subjects: 238
Study: 31705746

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 28470591

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (HIT) for 8 weeks (3 × 10-min cycle-ergometer-HIT/week)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Unsupervised high-intensity interval training (HIT) for 8 weeks (3 × 10-min cycle-ergometer-HIT/week)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual care for 8 weeks
Number of subjects: 13
Study: 25766448

Group type: EXPERIMENTAL
Intervention: Cumin cyminum L. capsule (n = 26)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Orlistat120 capsule (n = 26)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 78
Study: 23289456

Group type: EXPERIMENTAL
Intervention: Parent-focused online interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child-focused online interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined parent and child-focused online interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21653691

Group type: EXPERIMENTAL
Intervention: gemcitabine plus cisplatin (GP)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: gefitinib
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: High tertile CFDNA group
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Baseline plasma CFDNA
Number of subjects: 134
Study: 18474492

Group type: EXPERIMENTAL
Intervention: ENF 180 mg qd
Number of subjects: 61

Group type: COMPARATOR
Intervention: ENF 90 mg bid
Number of subjects: 61
Study: 16401645

Group type: EXPERIMENTAL
Intervention: 200mg G115/0 mg glucose (ginseng)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0 mg G115/25 g glucose (glucose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 200 mg G115/25 g glucose (ginseng/glucose combination)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0mg G115/0 mg glucose (placebo)
Number of subjects: 27
Study: 12853380

Group type: EXPERIMENTAL
Intervention: 500 mg of slow-release clarithromycin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 10961441

Group type: EXPERIMENTAL
Intervention: Cerebrolysin®
Number of subjects: 0
Study: 8803506

Group type: EXPERIMENTAL
Intervention: Heavy occupational musculoskeletal loading
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: High general occupational physical demands
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity, aerobic power, or muscle strength characteristics
Number of subjects: 456
Study: 1615189

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 6367466

Group type: EXPERIMENTAL
Intervention: Tobramycin and ticarcillin (TT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Tobramycin and ticarcillin plus cephalothin (TTC)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Tobramycin and mezlocillin (TM)
Number of subjects: 225
Study: 31608447

Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract, curcumin, pine bark extract, methylsulfonylmethane (combined)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Boswellia serrata extract, curcumin, pine bark extract, methylsulfonylmethane (alone)
Number of subjects: 16
Study: 29688845

Group type: EXPERIMENTAL
Intervention: Community engagement intervention
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Control group (standard immunization program)
Number of subjects: 2700
Study: 27121185

Group type: EXPERIMENTAL
Intervention: Affect school with script analysis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Basic body awareness treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 64
Study: 25014001

Group type: EXPERIMENTAL
Intervention: Escitalopram (10‐20 mg/d)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 22513879

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hyaluronic acid injections
Number of subjects: 120
Study: 19915909

Group type: EXPERIMENTAL
Intervention: Adequate generation of the allocation sequence
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Adequate allocation concealment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Adequate blinding
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Adequate sample size calculation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Disclosure of funding source
Number of subjects: 64
Study: 18853315

Group type: EXPERIMENTAL
Intervention: Topical lomefloxacin 0.3%
Number of subjects: 79

Group type: COMPARATOR
Intervention: Chloramphenicol 0.2% with polymyxin B 2500 U/ml
Number of subjects: 79
Study: 15339466

Group type: EXPERIMENTAL
Intervention: Fufang Sishen Decoction (FFSSD), 6 g, b.i.d.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Propafenone, 150 mg, q 8 h
Number of subjects: 102
Study: 11145620

Group type: EXPERIMENTAL
Intervention: Direct access service for laparoscopic sterilization
Number of subjects: 232

Group type: COMPARATOR
Intervention: Routine referral (Control)
Number of subjects: 232
Study: 9647301

Group type: EXPERIMENTAL
Intervention: Serologically unconfirmed symptomatic URTI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raised antiviral antibody titres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not at risk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptomatic or serologically defined at risk periods
Number of subjects: 0
Study: 7954995

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 60 micrograms.kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 2678834

Group type: EXPERIMENTAL
Intervention: DDP alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: DDP in combination with adriamycin (ADM) and cyclophosphamide
Number of subjects: 135
Study: 323994

Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29475854

Group type: EXPERIMENTAL
Intervention: Irrigation of major salivary glands with saline
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Irrigation of major salivary glands with saline followed by triamcinolone acetonide (TA) in saline
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study: 26860808

Group type: EXPERIMENTAL
Intervention: Flaxseed (25 g daily)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Vitex agnus (3.2‐4.8 mg daily)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (placebo for both)
Number of subjects: 159
Study: 24225451

Group type: COMPARATOR
Intervention: MNP (Micronutrient Powder)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MNP+Zn (Micronutrient Powder with 10 mg of zinc)
Number of subjects: 19
Study: 22431798

Group type: EXPERIMENTAL
Intervention: WC2031 (doxycycline hyclate delayed-release 200-mg tablet) orally once daily for 7 days
Number of subjects: 495

Group type: COMPARATOR
Intervention: Vibramycin (doxycycline hyclate capsule) 100 mg orally twice daily for 7 days
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: WC2031
Number of subjects: 495

Group type: COMPARATOR
Intervention: Vibramycin
Number of subjects: 495
Study: 20385634

Group type: EXPERIMENTAL
Intervention: Animated video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pamphlet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18705027

Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 250 mg once daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 500 mg once daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 1000 mg once daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 15782519

Group type: EXPERIMENTAL
Intervention: Modified Schirmer test (MST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (healthy adult volunteers)
Number of subjects: 61
Study: 12538185

Group type: EXPERIMENTAL
Intervention: 6% sevoflurane with large N(2)O concentration
Number of subjects: 18

Group type: COMPARATOR
Intervention: 6% sevoflurane with small N(2)O concentration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: N(2)O
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 18
Study: 10807486

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 220
Study: 8971298

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight of midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 40
Study: 1611111

Group type: EXPERIMENTAL
Intervention: 100 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Number of subjects: 87

Group type: COMPARATOR
Intervention: 10 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Number of subjects: 87

Group type: COMPARATOR
Intervention: Low-dose group (10 MU)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: High-dose group (100 MU)
Number of subjects: 87
Study: 6704008

Group type: EXPERIMENTAL
Intervention: Topical 0.25% betaxolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31653510

Group type: EXPERIMENTAL
Intervention: Vaccine-KLH conjugate + OPT-821
Number of subjects: 171

Group type: COMPARATOR
Intervention: OPT-821
Number of subjects: 171
Study: 29449096

Group type: EXPERIMENTAL
Intervention: Diabetes Conversation Maps (CMs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional Group Education (TE)
Number of subjects: 21
Study: 27050630

Group type: EXPERIMENTAL
Intervention: F/TDF+LPV/r
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: F/TDF+DRV/r
Number of subjects: 30
Study: 25108545

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 mcg
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 21535998

Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (SR) for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 32
Study: 19948566

Group type: EXPERIMENTAL
Intervention: Management model proposed by the ESC
Number of subjects: 941
Study: 17622274

Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ferric gluconate
Number of subjects: 12
Study: 16234333

Group type: EXPERIMENTAL
Intervention: 0.5 h infusion of 0.5 g every 6 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 h infusion of 0.5 g every 6 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 h infusion of 1 g every 6 h
Number of subjects: 8
Study: 11834876

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg over 10 min)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Norepinephrine infusion (0.1 microg/kg/min over 60 min)
Number of subjects: 5
Study: 10023946

Group type: EXPERIMENTAL
Intervention: Insecticide application in sprayed villages (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsprayed villages (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baited fly traps in Group A villages (1997)
Number of subjects: 0
Study: 7771621

Group type: COMPARATOR
Intervention: Controlled pancreaticocutaneous fistula (CPF)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 35
Study: 3605131

Group type: EXPERIMENTAL
Intervention: Extra snack at bedtime if capillary blood glucose levels at 10:30 P.M. were 120 mg/dl or less
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual routine of one evening snack at 9 P.M.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Capillary blood glucose concentration at 10:30 P.M.
Number of subjects: 20
Study: 30005634

Group type: EXPERIMENTAL
Intervention: Corneal steep‐axis incision (group A2)
Number of subjects: 77

Group type: COMPARATOR
Intervention: 135° incision (group B2)
Number of subjects: 77
Study: 26459247

Group type: EXPERIMENTAL
Intervention: 45-minute fast
Number of subjects: 24

Group type: COMPARATOR
Intervention: 6-hour fast (control)
Number of subjects: 24
Study: 24114251

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) application over the wound during total knee arthroplasty (TKA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no PRP application)
Number of subjects: 40
Study: 24377675

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Propofol TCI sedation
Number of subjects: 64
Study: 20572368

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol (50 mg/day) and medroxy progesterone acetate (2.5 mg/day) for 3 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (both transdermal and oral)
Number of subjects: 42
Study: 18323719

Group type: EXPERIMENTAL
Intervention: Nutrition education program (5 monthly sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine outpatient follow-ups (control)
Number of subjects: 64
Study: 19654220

Group type: EXPERIMENTAL
Intervention: Goal setting intervention
Number of subjects: 664
Study: 15569875

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard rehabilitation alone (control)
Number of subjects: 46
Study: 11573524

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 25
Study: 9388801

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity counseling
Number of subjects: 235

Group type: COMPARATOR
Intervention: Structured exercise program
Number of subjects: 235
Study: 7695927

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia with potassium (CBC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold blood only
Number of subjects: 40
Study: 3098401

Group type: EXPERIMENTAL
Intervention: Cutter factor VIII
Number of subjects: 49

Group type: COMPARATOR
Intervention: Connaught factor VIII
Number of subjects: 49
Study: 11290878

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 2,000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31326059

Group type: EXPERIMENTAL
Intervention: Fluoride varnish and 1450-ppm fluoride toothpaste
Number of subjects: 0
Study: 30136291

Group type: EXPERIMENTAL
Intervention: Oral taurine supplementation (2 g/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 27428211

Group type: EXPERIMENTAL
Intervention: Vaginal rings containing 25 mg dapivirine (DPV)/100 mg maraviroc (MVC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vaginal rings containing DPV only
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vaginal rings containing MVC only
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25456370

Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m² per day, adjusted for tolerability to attain blood trough concentrations of 5-15 ng/mL)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 111
Study: 22592573

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron in saline
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol in saline
Number of subjects: 135

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 135
Study: 20196917

Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trp-balanced placebo (Pla)
Number of subjects: 22
Study: 17914514

Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Surgical tracheostomy (ST)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both groups (ST and PDT)
Number of subjects: 205
Study: 15678233

Group type: EXPERIMENTAL
Intervention: Laboratory biofeedback alone (group 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Laboratory plus home biofeedback (group 2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (Laboratory biofeedback alone and Laboratory plus home biofeedback)
Number of subjects: 36
Study: 12217282

Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 67
Study: 9436865

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination (Ethanol + Nifedipine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 7787469

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 2652029

Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long‐acting gas
Number of subjects: 0
Study: 1204278

Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nabilone 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nabilone 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg or 2 mg two times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nabilone 5 mg after 7-day drug period
Number of subjects: 0
Study: 31916452

Group type: EXPERIMENTAL
Intervention: Early activity postinjury with a home exercise program involving progressive loading exercises after cast removal
Number of subjects: 129
Study: 31948903

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg plus placebo every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Number of subjects: 600

Group type: COMPARATOR
Intervention: Dual placebo every 4 weeks for 4 cycles, followed by single placebo every 4 weeks
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival rates, objective response rate, and safety and tolerability
Number of subjects: 600
Study: 31058448

Group type: EXPERIMENTAL
Intervention: Zoledronic acid injection (100 mL/5 mg) after operation, along with oral calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Number of subjects: 482
Study: 28845470

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (educational webinar for dialysis medical directors, educational video for patients, educational video for dialysis staff, dialysis-facility specific transplant performance feedback report)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 600
Study: 25586811

Group type: EXPERIMENTAL
Intervention: Telehealth services (health monitoring and patient safety)
Number of subjects: 859

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 859
Study: 23444004

Group type: EXPERIMENTAL
Intervention: RULER Approach to Social and Emotional Learning
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard ELA curriculum
Number of subjects: 62